Zadnja posodobitev :
08/05/2024
Antimuskarinik   Benztropine mesylate  
Brizgalka
Stabilnost raztopine Stabilnost mešanice Faktorji, ki vplivajo na stabilnost Kompatibilnost Način aplikacije Viri Pdf
   Kemična formula  

Lastniško ime   Lastniško ime     

Sestava pomožnih snovi je med paralelami lahko različna

Cogentin Kanada, Združene države Amerike
Viri   Brizgalka   Viri : Benztropine mesylate  
Tip Objava
188 časopis Gibler B, Kim MS, Raleigh F.
Visual compatibility of neuroleptics with anticholinergics or antihistamines in polyethylene syringes.
Am J Hosp Pharm 1994 ; 51: 2709-2710.
229 časopis Jackson CW, Cunningham K.
Compatibility of haloperidol lactate with benztropine mesylate.
Am J Hosp Pharm 1994 ; 51: 2962-2963.
479 časopis Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
496 časopis Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
1643 časopis Raleigh F, Gibler B.
Haldol-benztropine incompatibility.
Hosp Pharm 1994 ; 29: 76.
1724 časopis Elbe D, Condé C.
Visual compatibility of various injectable neuroleptic agents with benztropine and lorazepam in polypropylene syringes.
Can J Hosp Pharm 2001 ; 54: 102-105.
3012 časopis Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3964 časopis Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4319 časopis Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389 časopis Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213

  Mentions Légales